Alamar Biosciences assay links blood biomarker to advanced CTE pathology in study
ALMR•A study of 21 former football players found that higher blood levels of eMTBR-tau, measured with Alamar Biosciences’ NULISA assay, tracked greater brain tau tangle burden. The assay is not available for clinical use, and the findings require validation in larger, diverse groups.
1. Study findings
Alamar Biosciences announced results from a published JAMA study linking blood eMTBR-tau measured with its NULISA assay to advanced chronic traumatic encephalopathy (CTE) pathology. The study involved 21 former football players, and researchers said higher blood levels tracked greater brain tau tangle burden.
2. Limits of the findings
The findings could support CTE treatment research but require validation in larger, diverse groups. The assay is not available for clinical use, and no blood test has been validated to diagnose CTE in living patients.




